title: Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.
abstract: OBJECTIVE
  The primary objective of this study was to demonstrate the clinical and radiologic efficacy of 5 days compared with 7 days of gemifloxacin therapy in the treatment of acute bacterial rhinosinusitis (ABRS).
  
  
  METHODS
  In this prospective, double-blind, multicenter, parallel-group study, adult patients presenting with ABRS were randomized to receive gemifloxacin 320 mg once daily for either 5 days (n = 218) or 7 days (n = 203).
  
  
  RESULTS
  For the primary efficacy end point, clinical response to therapy at follow-up, 5 days of therapy with gemifloxacin was as effective as 7 days of therapy (per-protocol population; treatment difference 0.44%; 95% confidence interval [CI], -6.54 to 7.41). Five and 7 days of treatment with gemifloxacin were well tolerated.
  
  
  CONCLUSIONS
  The clinical efficacy of gemifloxacin 320 mg daily for 5 days is at least as good as the efficacy of gemifloxacin 320 mg daily for 7 days in the treatment of ABRS.
authors.affiliation: University of Pittsburgh School of Medicine, Ear, Nose, and Throat Specialists of Northwestern PA, 15213, USA. bjferg@vms.cis.pitt.edu
authors.forename: Berrylin J
authors.initials: BJ
authors.lastname: Ferguson
authors.forename: Jack
authors.initials: J
authors.lastname: Anon
authors.forename: Michael D
authors.initials: MD
authors.lastname: Poole
authors.forename: Kim
authors.initials: K
authors.lastname: Hendrick
authors.forename: Martyn
authors.initials: M
authors.lastname: Gilson
authors.forename: Elyse G
authors.initials: EG
authors.lastname: Seltzer
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D000077735:Gemifloxacin; D006801:Humans; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000008:administration & dosage*; D011336:Probability; D011446:Prospective Studies; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin